The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies.
The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
eTN Chatroom for Readers (join us)
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.
Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018 includes:
- Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2012
- Analysis of personalized medicine in oncology deal structure
- Case studies of real-life personalized medicine in oncology deals
- Access to over 700 personalized medicine in oncology deals
- The leading personalized medicine in oncology deals by value since 2012
- Most active personalized medicine in oncology dealmakers since 2012
- The leading personalized medicine in oncology partnering resources
In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018, the available contracts are listed by:
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Specific technology target
For more information about this report visit https://www.researchandmarkets.com/research/25tj78/global?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-personalized-medicine-in-oncology-partnering-terms-and-agreements-directory-2018—access-to-over-700-deals-since-2012-300615301.html
SOURCE Research and Markets
To post and circulate your own press release on FIR and the eTN Network please click here